Clinically significant pharmacokinetic interactions between dietary caffeine and medications

Clinical Pharmacokinetics

Volumn 39, Issue 2, 2000, Pages 127-153

  Carrillo, J A ^a   Benitez, J ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIARRHYTHMIC AGENT; BRONCHODILATING AGENT; CAFFEINE; CIPROFLOXACIN; CITALOPRAM; CLOZAPINE; ENOXACIN; FLEROXACIN; FLUOXETINE; FLUVOXAMINE; FURAFYLLINE; IDROCILAMIDE; LANSOPRAZOLE; LITHIUM; MEXILETINE; NEUROLEPTIC AGENT; OMEPRAZOLE; PANTOPRAZOLE; PAROXETINE; PHENYLPROPANOLAMINE; PROPAFENONE; PSORALEN DERIVATIVE; QUINOLONE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; UNINDEXED DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; DELIRIUM; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; FOOD DRUG INTERACTION; FOOD INTAKE; HEART ARRHYTHMIA; HUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE; SPORTS MEDICINE;

EID: 0033823375     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039020-00004     Document Type: Review

References (268)

1. Seventh International Caffeine Workshop, Santorini, Greece 13-17 June 1993
2. Clinical pharmacology of caffeine
3. Methylxanthines: Toxicity to humans. 2. Caffeine
4. Caffeine and the elderly
5. Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines
6. The consumption of coffee
7. Caffeine consumption
8. Drugs used in the treatment of asthma
9. Pharmacological rationale for the clinical use of caffeine
10. Central nervous system stimulants and anorectic agents
11. Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs
12. Mechanism of action of caffeine
13. Caffeine and cardiac arrhythmias
14. Effects of caffeine with repeated dosing
15. Sympathomimetic effects of paraxanthine and caffeine in humans
16. Pharmacoepidemiology of the effect of caffeine on blood pressure
17. Caffeine as an analgesic adjuvant: A review of pharmacology and mechanisms of action
18. Are we dependent upon coffee and caffeine? A review on human and animal data
19. Tolerance to the humoral and hemodynamic effects of caffeine in man
20. Pharmacokinetic-pharmacodynamic modeling of caffeine: Tolerance to pressor effects
21. Low-dose caffeine physical dependence in humans
22. Physical dependence increases the relative reinforcing effects of caffeine versus placebo
23. Caffeine withdrawal: A parametric analysis of caffeine dosing conditions
24. Caffeine self-administration and withdrawal: Incidence, individual differences and interrelationships
25. Increased anxiogenic effects of caffeine in panic disorders
26. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine
27. Five cases of fatal overdose from caffeine-containing 'look-alike' drugs
28. Caffeine poisoning in infants resulting from confusion between dosage forms. Aropos of 5 cases
29. Caffeine poisoning in a 19-year-old female
30. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva and urine
31. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse
32. Relationship between caffeine concentrations in plasma and saliva
33. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva
34. Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity
35. Caffeine: A new look at an age-old drug
36. Quantitative assessment of caffeine partial clearances in man
37. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways
38. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1
39. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines
40. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes
41. Accumulation of caffeine in healthy volunteers treated with furafylline
42. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man
43. The use of caffeine for enzyme assays: A critical appraisal
44. A simple test for acetylator phenotype using caffeine
45. Metabolism of caffeine and other components of coffee
46. Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2; Evidence from cDNA-directed expression in Saccharomyces cerevisiae
47. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2
48. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy
49. Metabolic activation of carcinogens
50. Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens
51. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
52. The aryl hydrocarbon receptor complex
53. Activation of carcinogens by human liver cytochromes P-450
54. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2
55. Bioequivalence evaluation of two flutamide preparations in healthy female subjects
56. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP 2C19 and 3A4
57. Clinical pharmacokinetics of antidepressants in the elderly: Therapeutic implications
58. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways
59. Clinical significance of plasma levels of clomipramine, its hydroxylated and desmethylated metabolites: Prediction of clinical outcome in mood disorders using discriminant analysis of therapeutic drug monitoring data
60. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity
61. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms
62. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers
63. Pharmacokinetic optimisation of therapy with newer antidepressants
64. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver
65. Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics
66. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test
67. Will routine therapeutic drug monitoring have a place in clozapine therapy?
68. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
69. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients
70. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia
71. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine
72. Olanzapine plasma concentrations and clinical response in acutely schizophrenic patients
73. Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication
74. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients
75. Plasma level monitoring of antipsychotic drugs: Clinical utility
76. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans
77. Ondansetron clinical pharmacokinetics
78. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: Comparison of those with rat hepatic cytochrome P-450s
79. Antiarrhythmic prophylaxis after acute myocardial infarction: Is lidocaine still useful?
80. Involvement of CYP1A2 in mexiletine metabolism
81. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine
82. Clinical pharmacokinetics of mexiletine
83. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: Molecular base for interaction potential and variable disposition of active metabolites
84. Propafenone: A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias
85. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes: The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase
86. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes: Enantioselectivity and quinidine inhibition
87. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers: N-desisopropylation is mediated mainly by CYP1A2
88. Triamterene hydroxylation in human liver microsomes is mediated by the cytochrome P450 isoform CYP1A2
89. Identification of P450 enzymes involved in metabolism of verapamil in humans
90. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe
91. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes
92. Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease
93. Clinical pharmacokinetics of tacrine
94. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes
95. Intraindividual and interindividual variability in the disposition of the local anesthetic ropivacaine in healthy subjects
96. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics
97. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2
98. Pefloxacin clinical pharmacokinetics
99. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes
100. The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease
101. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine
102. Metabolism of theophylline by cDNA-expressed human cytochromes P-450
103. Variability in caffeine metabolism
104. Variability of caffeine metabolism in humans
105. Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites
106. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans
107. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test
108. Cytochrome P450 IA2 activity in man measured by caffeine metabolism: Effect of smoking, broccoli and exercise
109. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine
110. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: Inverse associations with plasma lutein and alpha-tocopherol
111. Impact of long-term ethanol consumption on CYP1A2 activity
112. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man
113. Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans
114. Heterocyclic amines, cytochrome P4501A2, and N-acetyltransferase: Issues involved in incorporating putative genetic susceptibility markers into epidemiological studies
115. The effect of liver disease on urine caffeine metabolite ratios
116. Menstrual cycle effects on caffeine elimination in the human female
117. The disposition of caffeine during and after pregnancy
118. Changes in rate and pattern of caffeine metabolism after cigarette abstinence
119. Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking
120. P450 gene induction by structurally diverse xeno-chemicals: Central role of nuclear receptors CAR, PXR, and PPAR
121. Role of well-done, grilled red meat, heterocyclic amines (HCAs) in the etiology of human cancer
122. Inhibition and induction of cytochrome P450 and the clinical implications
123. Molecular genetics of the human cytochrome P450 monooxygenase superfamily
124. Are antipsychotic drugs potentially chemopreventive agents for cancer?
125. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities
126. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography
127. Influence of the menstrual cycle on theophylline pharmacokinetics in asthmatics
128. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1
129. Tumor-specific expression of cytochrome P450 CYP1B1
130. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes
131. Antimicrobial agents: Sulfonamides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections
132. Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine
133. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism
134. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
135. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2
136. The effect of fluconazole on the pharmacokinetics of caffeine in young and elderly subjects
137. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers
138. Diltiazem treatment impairs theophylline elimination in patients with bronchospastic airway disease
139. Influence of mexiletine on caffeine elimination
140. Verapamil-induced inhibition of theophylline elimination in healthy humans
141. Interaction between caffeine and clozapine
142. Comments to 'interaction between caffeine and clozapine'
143. Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine
144. A fluvoxamine-caffeine interaction study
145. Are adverse drug reactions attributed to fluvoxamine caused by concomitant intake of caffeine?
146. CYP1A2 activity and smoking influence the risk/benefit ratio of olanzapine in schizophrenic patients
147. Unsuspected caffeine toxicity complicating theophylline therapy
148. Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects
149. Decreased systemic clearance of caffeine due to cimetidine
150. Effects of cimetidine on caffeine disposition in smokers and nonsmokers
151. Inhibition by idrocilamide of the disposition of caffeine
152. Impaired elimination of caffeine by oral contraceptive steroids
153. Comparison of caffeine metabolism in three nonsmoking populations after oral administration of radiolabeled caffeine
154. Impairment of caffeine clearance by chronic use of low-dose oestrogen- containing oral contraceptives
155. Manic psychosis after coffee and phenylpropanolamine
156. Phenylpropanolamine increases plasma caffeine levels
157. Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans
158. Psoralens and related compounds in the treatment of psoriasis
159. Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis
160. Clinical pharmacokinetics of lansoprazole
161. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450
162. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin
163. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test
164. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man
165. Interaction between quinolones and caffeine
166. Interaction between oral ciprofloxacin and caffeine in normal volunteers
167. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine
168. Theophylline and warfarin interaction studies with grepafloxacin
169. Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline
170. The effects of quinolones on xanthine pharmacokinetics
171. Effect of quinolones on caffeine disposition
172. 4-Quinolones inhibit biotransformation of caffeine
173. Decrease of caffeine elimination in man during co-administration of 4-quinolones
174. Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition
175. Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration
176. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine
177. Comparative studies on interaction between theophylline and quinolones
178. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers
179. Influence of caffeine on aspirin pharmacokinetics
180. Effect of caffeine on the bioavailability and pharmacokinetics of aspirin
181. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients
182. Clozapine levels and caffeine
183. Caffeine withdrawal increases lithium blood levels
184. Lithium tremor and caffeine intake: Two cases of drinking less and shaking more
185. The effect of caffeine on the pharmacokinetics of acetaminophen in man
186. The influence of caffeine on the steady-state pharmacokinetics of theophylline
187. Inhibition and induction of human cytochrome P450 (CYP) enzymes
188. Effect of allopurinol on caffeine disposition in man
189. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities
190. Effect of caffeine on xanthine oxidase activity
191. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities
192. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: Probe of CYP3A
193. Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers
194. Theophylline-mexiletine interaction: A case report
195. Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2
196. The effect of three different oral doses of verapamil on the disposition of theophylline
197. Effects of caffeine in chronic psychiatric patients
198. Possible psychiatric significance of excessive coffee consumption
199. Anxiety and depression associated with caffeinism among psychiatric inpatients
200. Measurement of coffee and caffeine intake: Implications for epidemiologic research
201. Caffeine and schizophrenia
202. Response to 'effects of caffeine on behavior of schizophrenic inpatients'
203. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors
204. Selective serotonin reuptake inhibitors and CNS drug interactions
205. Fluvoxamine: A review of global drug-drug interaction data
206. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
207. Inhibitors of imipramine metabolism by human liver microsomes
208. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
209. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine
210. Differences in interactions of SSRIs
211. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service
212. Elevated levels of clozapine in serum after addition of fluvoxamine
213. Interaction of phenothiazine and related drugs and caffeinated beverages
214. Precipitation of antipsychotic drugs in interaction with coffee or tea
215. Genetically variable metabolism of antidepressants and neuroleptic drugs in man
216. Disposition of clozapine in man: Lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms
217. Clozapine plasma levels and convulsions
218. Therapeutic drug monitoring of clozapine treatment: Therapeutic threshold value for serum clozapine concentrations
219. Seizures following smoking cessation in a clozapine responder
220. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A
221. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
222. Disposition and biotransformation of the antipsychotic agent olanzapine in humans
223. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men
224. Renal lithium excretion in man
225. Cimetidine-theophylline interaction: Report of four patients
226. Cimetidine-theophylline interaction in patients with chronic obstructive airways disease
227. Differential effects of cimetidine on theophylline metabolic pathways
228. Lack of inhibitory effect of cimetidine on caffeine metabolism in children using the caffeine breath test
229. Famotidine and theophylline pharmacokinetics: An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease
230. Characterisation of theophylline metabolism by human liver microsomes: Inhibition and immunochemical studies
231. Gender effects in pharmacokinetics and pharmacodynamics
232. A population and family study of CYP1A2 using caffeine urinary metabolites
233. Oral contraceptive steroids impair the elimination of theophylline
234. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination
235. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy
236. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women
237. Severe hypertension after ingestion of an appetite suppressant (phenylpropanolamine) with indomethacin
238. The effect of multiple doses of phenylpropanolamine on the blood pressure of patients whose hypertension was controlled with beta blockers
239. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture
240. Four-week treatment with omeprazole increases the metabolism of caffeine
241. Regulation of dioxin receptor function by omeprazole
242. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: Focus on omeprazole, lansoprazole and pantoprazole
243. Omeprazole and lansoprazole are not inducers of cytochrome P4501 A2 under conventional therapeutic conditions
244. Theophylline steady state pharmacokinetics is not altered by omeprazole
245. Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers
246. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
247. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline
248. Inhibition and induction of theophylline metabolism by 8-methoxypsoralen: In vivo study in rats and humans
249. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis
250. Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives
251. The drug methoxsalen, a suicide substrate for cytochrome P-450, decreases the metabolic activation, and prevents the hepatotoxicity, of carbon tetrachloride in mice
252. Inactivation of cytochrome P-450 by the drug methoxsalen
253. Pronounced effect of oral but not of bath PUVA (methoxsalen plus UVA) on CYP1A2 activity in dermatological patients
254. The influence of quinolone derivatives on theophylline clearance
255. Overview of drug interactions with the quinolones
256. Interaction of quinolones with the theophylline metabolism in man: Investigations with lomefloxacin and pipemidic acid
257. Influence of lomefloxacin on the pharmacokinetics of theophylline
258. Ofloxacin clinical pharmacokinetics
259. Drug-drug interactions with fluoroquinolones
260. Lack of interaction between lomefloxacin and caffeine in normal volunteers
261. Effect of lomefloxacin on theophylline pharmacokinetics
262. Fluoroquinolone toxicity profiles: A review focusing on newer agents
263. Convulsions related to enoxacin
264. Central nervous system toxicity of quinolones: Human and animal findings
265. Caffeine renal clearance and urine caffeine concentrations during steady state dosing: Implications for monitoring caffeine intake during sports events
266. Caffeine and sport: Role of physical exercise upon elimination